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Abstract 
Background: Peripheral neuropathy is a common and dose-limiting side effect of many cancer chemotherapies. The 
taxane agents, including paclitaxel (Taxol®), are effective chemotherapeutic drugs but cause degeneration of pre-
dominantly large myelinated afferent sensory fibers of the peripheral nervous system in humans and animal models. 
Dorsal root ganglia (DRG) neurons are sensory neurons that have unipolar axons each with two branches: peripheral 
and central. While taxane agents induce degeneration of peripheral axons, whether they also cause degeneration of 
central nervous system axons is not clear. Using a mouse model of paclitaxel-induced neuropathy, we investigated 
the effects of paclitaxel on the central branches of sensory axons.
Results: We observed that in the spinal cords of paclitaxel-intoxicated mice, degenerated axons were present in 
the dorsal columns, where the central branches of DRG axons ascend rostrally. In the peripheral nerves, degenerated 
myelinated fibers were present in significantly greater numbers in distal segments than in proximal segments indicat-
ing that this model exhibits the distal-to-proximal degeneration pattern generally observed in human peripheral 
nerve disorders.
Conclusions: We conclude that paclitaxel causes degeneration of both the peripheral and central branches of DRG 
axons, a finding that has implications for the site and mode of action of chemotherapy agents on the nervous system.
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Background
Chemotherapy-induced peripheral neuropathy (CIPN) 
is often a factor in limiting cancer therapy with chemo-
therapeutic drugs, particularly for effective taxane agents 
such as paclitaxel (Taxol®) [1, 2]. CIPN, like most other 
neuropathies, is characterized by the degeneration of 
axons, often resulting in sensory or sensory-motor neu-
ropathy in patients. The incidence of CIPN is influenced 
by a number of factors including dose intensity, cumula-
tive dose, duration of therapy, and co-administration of 
other neurotoxic chemotherapeutic drugs [3]. Depending 
on drug dosage and the agent used, symptoms may 
resolve completely in some cases, but some cases of 
CIPN are only partly reversible [4]. For such patients, 
symptoms may persist for a lifetime and cause significant 
functional impairment and decreased quality of life [5].
Paclitaxel is an effective taxane chemotherapy agent 
approved for the treatment of breast, ovarian, non-small 
cell lung carcinomas and Kaposi’s sarcoma. Unfortu-
nately, patients often experience paresthesias, numbness 
and/or spontaneous pain in a stocking-and-glove dis-
tribution, as well as sensory deficits including loss of 
temperature sensation, decreased vibration perception 
and sense of position as a result of treatment [6]. Some 
patients develop neuropathy after only a single adminis-
tration of the drug, especially when in combination with 
other chemotherapeutic drugs [4].
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In an effort to study the mechanisms responsible for 
the development of CIPN, numerous animal models 
have been developed over the years. Rodent models of 
paclitaxel-induced neuropathy, in particular, show var-
ied degrees of axonal degeneration depending on the 
dose and treatment schedule. For example, distal axonal 
degeneration in footpads with no degenerative effects in 
the sciatic nerve was reported in mice intoxicated with 
25 mg/kg body weight administered 3 times per week for 
1 week [7]. In rats injected with 2 mg/kg body weight of 
paclitaxel daily for 6 days, swollen and vacuolated axonal 
mitochondria were observed with no other reported 
degeneration [8]. Finally, paclitaxel at a high dose of 
60  mg/kg body weight administered 3 times in a single 
week caused severe degeneration of axons in mice, com-
pared to little axon degeneration seen in mice receiv-
ing a low dose of 30 mg/kg 3 times in 1 week [9]. Taken 
together, previous studies promote the usage of moder-
ately high doses for pathology investigations. Addition-
ally, dose-dependent adverse effects have been observed 
in the DRG cell bodies of mice. At lower doses (lower 
than the maximum tolerated dose), dark inclusions as 
well as clear vacuolations in the cytoplasm of neurons 
and satellite cells have been observed. At relatively high 
doses (at the maximum tolerated dose), a proportion of 
the cytoplasms of DRG neurons appeared much darker 
than that of normal neurons and a few degenerating neu-
ronal cells were reported [10].
Non-neuronal cells in the nervous system are also 
affected by chemotherapy agents. Rats injected with 
paclitaxel have increased numbers of activated micro-
glia and astrocytes in the dorsal horn of the spinal cord, 
as compared to that of vehicle-treated rats [11, 12]. Acti-
vated macrophages appear in both DRG and the sciatic 
nerves of paclitaxel-intoxicated rats at 18  mg/kg body 
weight administered 2 times, 3  days apart [11, 12]. In 
treated rats, Schwann cells in the sciatic nerves and sat-
ellite cells of DRG express ATF3, a transcription factor 
not normally expressed in these cells [11, 12]. While the 
findings of previous studies have been extensive, they 
have been mostly limited to peripheral axons, Schwann 
cells in the sciatic nerve, DRG cell bodies, and non-neu-
ronal cells in the spinal cord; the effect of taxanes on the 
central branch of DRG sensory axons has not yet been 
elucidated.
Recently, we developed a paclitaxel-induced neuropa-
thy mouse model that recapitulates aspects of human 
CIPN. In this model, large and small myelinated axons 
degenerate and there are pronounced deficits in nerve 
conduction velocity of caudal and digital nerves [10]. In 
the present study, we performed morphological analyses 
of the sciatic nerve and DRG following paclitaxel admin-
istration in this model. Symptoms of paclitaxel treatment 
are shown to manifest in peripheral neuropathy [1, 2], 
but sensory information is transmitted through the cen-
tral branch of DRG axons to the central nervous system. 
Given the degenerative effect of paclitaxel on peripheral 
sensory axons, we asked whether the central branches of 
DRG axons are also affected.
Results
We sought to determine whether the chemotherapy 
agent paclitaxel causes degeneration of central nerv-
ous system axons, particularly those that carry sensory 
information to higher brain regions. We adapted a well-
described mouse model of paclitaxel-induced neuropathy 
[10], in which mice were treated for 2 weeks and tissue 
samples were harvested for analysis one day after the end 
of treatment.
Axonal degeneration in the spinal cord
Each DRG neuron has a unipolar axon with two branches: 
peripheral and central. Given the degenerative effect of 
paclitaxel on peripheral sensory axons, we asked whether 
the central branches of DRG axons are also affected. We 
examined representative sections of spinal cords at all 
levels, and degeneration was observed at all representa-
tive levels. In semithin 1  μm plastic sections, degener-
ated myelin profiles were present in the dorsal column, 
where central branches of DRG axons ascend rostrally 
(Fig.  1a–f). Within the spinal cord, degenerated myelin 
profiles, the footprint of degenerated myelinated axons, 
were restricted to the dorsal column. None were present 
in the ventral horn or lateral columns (Fig. 2A), indicat-
ing that the toxic effects of paclitaxel were restricted to 
ascending sensory axons (Fig. 1a–f). Further, the pattern 
of degeneration in the dorsal column spanned medial and 
lateral areas of the dorsal column. 
As degenerated myelin profiles are not cleared from 
and persist for years in the central nervous system [13, 
14], we examined spinal cords 2 months after paclitaxel 
treatment, and found degenerated myelin profiles in the 
dorsal column (data not shown). Our findings suggest 
that chemotherapy agents can cause degeneration of sen-
sory axons in the central nervous system in addition to 
the known degeneration of peripheral axons.
Next, we examined the ultra-structural morphol-
ogy of degenerated axons in the spinal cords of mice 
intoxicated with paclitaxel under the electron micro-
scope. We observed axons at various stages of degenera-
tion. Axoplasms filled with organelles and disintegrated 
amorphous granular structures were present with intact 
myelin (Fig. 2B, C). Myelin ovoid profiles were also pre-
sent, some with folded and others with unwounded 
myelin. Degenerated axons were distributed throughout 
the entirety of the dorsal column, from the dorsal region 
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towards the medial central canal, indicating that both 
long axons and short ones were affected by paclitaxel tox-
icity. Taken together, these data suggest that paclitaxel 
causes degeneration of ascending sensory axons in the 
CNS.
Axonal degeneration in the sciatic nerve
CIPN is thought to affect distal axons first as symptoms 
initially appear at distal sites [1, 2]. We examined whether 
our model exhibits a distal-to-proximal degeneration 
pattern by counting degenerated axons in the sciatic 
nerves of paclitaxel-intoxicated mice at two segments, 
distal and proximal. Degenerated myelin profiles were 
present all over the cross-sectional areas of the nerves at 
both proximal (Fig.  3b) and distal (Fig.  3c) segments of 
paclitaxel-intoxicated nerves. On average, 4–5 % of fibers 
examined were degenerated. However, greater numbers 
of degenerated fibers were present in the distal segments 
as compared to that in the proximal segments (Fig. 3d), 
indicating that this model of paclitaxel-induced neu-
ropathy exhibits the well-described patterns of distal-to-
proximal degeneration seen in peripheral neuropathies 
Fig. 1 Degeneration of axons in the dorsal column of mice intoxicated with paclitaxel. Images are cross-sectioned semithin (1 µm) plastic sections 
of spinal cords stained for toluidine blue. a Control vehicle-treated (cremophor) spinal cord at lumbar level. No degenerated axons are observed. b 
Paclitaxel treated spinal cord. Degenerated myelin profiles are present in dorsal column of thoracic level where ascending central branches axons 
of DRG neurons reside. c Paclitaxel treated spinal cord. Degenerated myelin profiles are present in dorsal column of lumbar level where ascend-
ing central branches axons of DRG neurons reside. d High magnification of a showing no degenerated axons. e High magnification of b showing 
degenerated myelin profiles (arrows). f High magnification of c showing degenerated myelin profiles (arrows). Scale bar in c = 50 μm and applies to 
a–c. Scale bar in f = 10 μm and applies to d–f
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[13, 15]. Degenerated axons appeared to be of large- and 
medium-sized fiber classes (Fig.  3c, d). In intoxicated 
nerves examined under the electron microscope, very 
few swollen unmyelinated axons were present, and the 
vast majority of unmyelinated axons appeared normal 
(Fig. 3e, f ), consistent with observations that in humans, 
paclitaxel has minimal adverse effects on unmyelinated 
axons [1, 2].
Macrophages infiltrate sciatic nerves in animals intoxi-
cated with paclitaxel [11, 12]. In peripheral neuropathies, 
macrophages generally associate with degenerated fibers 
by invading basal lamina and ingesting axonal and mye-
lin debris [13, 16]. We asked whether paclitaxel induced 
a similar pattern of macrophage invasion in intoxicated 
nerves. In longitudinal sections, we stained for myelin 
basic protein (MBP) to identify both healthy and degen-
erated, fragmented myelinated axons in conjunction 
with CD68, a lysosomal protein present in activated and 
phagocytic macrophages [17]. We found macrophages 
infiltrating degenerating fibers in the midst of normal-
looking fibers (Fig. 4).
We next examined DRG for signs of neuronal cell body 
degeneration. We did not observe massive degeneration 
of neuronal cell bodies (Fig. 5), nor did we observe pyk-
notic nuclei or fragmented neuronal cells. Instead, we 
observed minor alterations such as small nucleoli in the 
large neurons of the paclitaxel-treated mice, supporting 
the notion that the predominant adverse action of pacli-
taxel is likely to be on axons, though we cannot exclude 
contributions from alterations in DRG.
Discussion
We show that paclitaxel can induce degeneration of the 
central axons of DRG neurons, building on previously 
described degenerative effects of taxanes on sensory 
neurons and axons. Previous work demonstrated that 
paclitaxel causes peripheral neuropathy that manifests as 
degeneration of afferent sensory axons [10]. The degree 
and reversibility of chemotherapy-induced peripheral 
neuropathy is dependent on the dose and treatment 
schedule of the chemotherapy agent; recovery is likely 
due to repair and regenerative capacities of peripheral 
sensory nerves, resulting in the restoration of some func-
tion [1, 2]. However, central axons have limited capac-
ity to repair and regenerate and any functional loss is 
unlikely to recover [18]. Our work on the mouse model 
of CIPN, therefore, highlights the critical need for novel 
approaches of central axonal protection from chemother-
apy agents, as opposed to the development of regenera-
tive strategies for peripheral axons only.
DRG neurons have a unique feature of possessing both 
central and peripheral axonal branches; thus, once inside 
a neuron, paclitaxel in sufficient doses would be expected 
Fig. 2 Electron microscope images of degenerated of axons in the 
dorsal column. A EM image showing healthy and no degenerated 
axons (arrows) and myelin ovoids in the ventral horn of lumbar region 
of mice intoxicated with paclitaxel. B Low magnification EM image 
showing degenerated axons (arrows) and myelin ovoids in the dorsal 
column of lumbar region. C High magnification EM images of lumbar 
level showing degenerated axons at various stages of degeneration. 
Arrowhead points to degenerated axoplasm filled with organelles. 
Arrow points to degenerated myelin profile that has already collapsed 
following degeneration of axoplasm
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to affect microtubules in the cell body and in both axonal 
branches. Our data suggest that this prediction holds 
in mouse models. The observation that degeneration is 
restricted to the dorsal column where DRG axons reside 
in the spinal cord suggests that paclitaxel does not affect 
spinal cord axons uniformly and probably does not 
Fig. 3 Paclitaxel causes distal to proximal axonal degeneration in mice. Mice were treated with i.v. 30 mg/kg paclitaxel 3 times a week for 2 weeks. 
a–c are cross-sectioned semithin (1 µm) plastic sections stained for toluidine blue. a Vehicle-treated (cremophor) mice at the mid-thigh level of 
sciatic nerve. No degenerated axons are observed. b Paclitaxel-treated mice at the mid-thigh level of sciatic nerve. Degenerated myelin pro-
files were present across the nerve crossed section. Arrows point to large (black arrow) and small (white arrow) degenerated myelinated axons. c 
Paclitaxel-treated mice at 7–8 mm distal to the sciatic nerve segment in a. Greater numbers of degenerated myelin profiles are present across the 
distal segment of the nerve, indicating distal to proximal degeneration pattern. d Quantification of degenerating myelinated fibers in the whole 
cross-sectional area of nerve segments. N = 3 per nerve segment. Values are mean ± SEM. e Electron micrograph of distal nerve intoxicated with 
paclitaxel showing occasional swollen unmyelinated axon (arrow) and degeneration of myelinated axon (*). f Quantification of Remak bundles. 
N = 3 mice per treatment. There was no statistical difference between vehicle- and paclitaxel-treated nerves. Scale bar in c = 20 μm and applies to 
a–c. Scale bar in e = 500 nm
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directly enter the central nervous system in sufficient 
amounts to cause a uniform toxicity. Indeed, paclitaxel 
has been shown in relatively low concentrations in the 
spinal cord compared to sciatic nerve and DRG in mice 
[2, 19]. Therefore, it is likely that paclitaxel can either be 
transported from the periphery or directly affect DRG 
cell bodies to cause degeneration of axons in the dorsal 
column. Our data cannot distinguish between these two 
routes, but support the notion that paclitaxel can exert 
degenerative effects on sensory axons irrespective of 
whether the axons are in the central or peripheral nerv-
ous systems.
A potential explanation for the degeneration of central 
DRG axons is that at the dose used in this study, pacli-
taxel may cause massive death of DRG neurons. However, 
our data argues against this notion as we did not observe 
degenerating neuronal cells bodies in the DRG of mice 
intoxicated with paclitaxel (Fig.  5). Other studies also 
report the absence of massive degeneration of DRG neu-
rons following high dose intoxication [10]. Therefore, in 
the paclitaxel-induced neuropathy mouse model exam-
ined, the degenerative effects of paclitaxel are exerted 
in part on central sensory axon branches. Importantly, 
the dose used in this study, 30 mg/kg 3 times a week for 
2 weeks, is equivalent to a mg/m2 human dose. Paclitaxel 
is dosed in human at 175–300 mg/m2 every 2–3 weeks; 
thus, the high dose investigated in this study remained 
within the range that is administered in human. In future 
studies, it would be interesting to test if similar effects are 
observed at different doses of paclitaxel intoxication.
In mouse dorsal column and likely in that of human, 
ascending mechanosensory axons are segregated from 
axons that transmit proprioceptive information in a 
medial to lateral pattern [20]. Our data suggest that 
both types of afferent axons degenerate as we observed 
degenerated axons in both medial and lateral regions of 
the dorsal column, and at all levels of the spinal cord of 
Fig. 4 Macrophages infiltration along degenerated axons in nerve 
intoxicated with paclitaxel. Longitudinal frozen sectioned nerve seg-
ment stained for CD68 and MBP. a MBP staining of nerve segment 
intoxicated with paclitaxel. The vast majority of fibers appear normal 
with the exception of a single fiber that show degenerated myelin 
(arrow). b CD68 staining. Macrophages (CD68-positive cells) infiltrate 
along a degenerating fiber, while not associating with other normal 
fibers (arrow). c Merged image of a and b. Scale bar 50 μm
Fig. 5 DRG cell bodies after paclitaxel intoxication. a Control DRG. b 
Paclitaxel intoxicated DRG. Minor alternations are seen such as small 
nucleoli in the large neurons of the paclitaxel-treated mice. Scale bar 
in b = 10 μm and applies to a, b
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paclitaxel-intoxicated mice. Our findings are consistent 
with observed effects of taxanes on both mechanorecep-
tion and proprioception in human cases [6].
Paclitaxel binds to microtubules and stabilizes them, 
which interferes with normal cellular function including 
cell division and microtubule-dependent intra-cellular 
and axonal transport [4, 6]. Through the aggregation of 
intracellular microtubules, taxanes affect both the soma 
of sensory neurons as well as axons [6]. Microtubule-
dependent transport is critical for axonal function and 
health, both in the central and peripheral nervous sys-
tems; as such, disruption of axonal transport is impli-
cated in various central nervous system disorders and 
peripheral neuropathies [21]. Agents such as paclitaxel 
that disrupt microtubule-dependent transport would 
be expected to affect both central and peripheral axons 
given that the agents have access to axons, either directly 
or via DRG cell bodies.
Involvement of non-neuronal cells in peripheral neu-
ropathy caused by paclitaxel in rodent models has been 
previously documented [11, 12]. Whether the adverse 
effect on non-neuroral cells within the nervous sys-
tem is a primary contributor or a secondary response 
to axonal injury, however, is an open question. Our data 
suggest that activated macrophages in paclitaxel-treated 
nerves are in response to degenerated axons and there-
fore, at least one cell type, macrophages, mediates sec-
ondary effects to the insult of paclitaxel on axons. Foamy 
phagocytic macrophages were associated with degener-
ating fibers, but not intact myelinated axons. This pat-
tern of macrophage infiltration has been described in 
other human peripheral neuropathies, including axonal 
neuropathies [13]. Therefore, macrophages in paclitaxel-
treated nerves might be clearing debris of degenerated 
axons and myelin, thus allowing for regeneration and 
recovery over time, and facilitating the resolution of 
peripheral neuropathy from taxanes in some cases.
Though our data is restricted to the mouse model of 
CIPN, the results have implications for patients under-
going aggressive chemotherapy treatment. In a few 
cases, degeneration of central axons has been reported 
in patients treated with chemotherapy agents. For exam-
ple, degeneration of the dorsal column of the spinal cord 
has been described in a patient treated with bortezomib, 
a proteasome inhibitor that is a very effective chemo-
therapy agent for multiple myeloma [22]. A limiting fac-
tor in identifying cases presenting with dorsal column 
degeneration has been the requirement for autopsy tis-
sue. However, with the availability of MRI imaging capa-
ble of detecting damage to the spinal cord [23], it is now 
possible to ascertain degeneration in the spinal cords of 
patients undergoing aggressive treatment. The data in 
our mouse model of CIPN argue for such examination.
Conclusions
The data from our mouse model of CIPN suggest that in 
addition to exerting degenerative effects on peripheral 
axons, the chemotherapeutic agent paclitaxel also causes 
degeneration of the central branches of dorsal root gan-
glia (DRG) ascending in the dorsal spinal cord. These 
findings contribute to the understanding of the site and 
mode of action of paclitaxel on the nervous system, and 
highlight the need to develop novel protective strate-




A total of 22 3–4  month old mice on C57Bl/6 back-
ground, both male and female, were used. The ani-
mal care procedures and experimental protocols were 
approved by the Animal Care and Use Committee of the 
Johns Hopkins University School of Medicine.
Paclitaxel administration
Paclitaxel (LC laboratories) was dissolved in 100 % etha-
nol. Equal volumes of paclitaxel solution and cremophor 
(Sigma-Aldrich) were vigorously vortexed for 10  min. 
Ice-cold saline (80  % of the final volume) was added to 
freshly made paclitaxel/cremophor solution immediately 
before injection. 30 mg/kg paclitaxel in this solution was 
injected intravenously via tail vein at 3 times a week for 
2 weeks. Survival time after treatment was 1 day.
Tissue processing
Mice were deeply anesthetized with 10 % chloral hydrate 
and killed by transcardial perfusion with 1×  PBS fol-
lowed by 4 % paraformaldehyde in 1× PBS. Tissues were 
post-fixed in the same fixative overnight. Sciatic nerves 
were cryoprotected in 30 % sucrose in 1× PBS, and sec-
tioned at 20  μm. Sciatic nerves were sectioned longitu-
dinally using a Leica cryostat (model CM3050S; Leica 
Microsystems). For semithin sections, nerves, DRG, and 
spinal cords were postfixed in 4 % paraformaldehyde/2 % 
glutaraldehyde followed by OsO4 and embedded in Epon. 
Cross sections, at 1 μm thickness, were stained for tolui-
dine blue and examined under light microscopy. For 
ultra-structural analyses, spinal cord and nerves were 
processed as described previously [24]. Briefly, 70  nm 
thin sections were obtained and stained for citrate/uranyl 
acetate. Electron micrographs were acquired using Zeiss 
Libra transmission electron microscope.
Quantification
Counts of degenerated axons across sectional areas of 
the entire nerves were quantified. Images taken at 60× 
oil-immersion lens were tiled to obtain montages that 
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cover the entire nerves. Degenerated myelin profiles were 
counted for each nerve at mid-thigh level and distal seg-
ments were taken at 7–8 mm away, and N = 3 for each 
segment examined. For unmyelinated axon counts, 100–
110 Remak bundles were imaged by EM from each nerve. 
The number of axons per Remak bundle was counted.
Staining protocol
For immunocytochemistry, nonspecific antibody bind-
ing was blocked by 5 % goat serum (Jackson labs)/0.3 % 
Triton (Sigma-Aldrich) in 1× PBS overnight at room 
temperature. Sections were then incubated with primary 
antibodies MBP (Millipore) and CD68 (AbD Serotec) 
overnight at 4  °C. After 3× PBS washes, sections were 
incubated with appropriate anti-rabbit and -rat second-
ary antibodies conjugated with Alexa Fluor 488 and 546 
(Life technologies) at a 1:2000 dilution for two hours at 
room temperature. Samples were washed three times in 
PBS, mounted (Prolong Antifade kit; Life technologies), 
and cover-slipped. Stained sections were examined under 
confocal microscope (LSM500, Zeiss).
Statistical analysis
All statistical analyses were performed using the Stu-
dent’s t test. SigmaPlot software was used to perform 
the analyses and any value of p  <  0.05 was scored as 
statistically significant. Graphed data are presented as 
mean ± SEM.
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